BaseSpace
Correlation
Engine-Public
Sign In
Register
Correlation Engine 2.0
Home
My Data
Bookmarks
Collaborations
Inbox
Import Your Data
QuickView
FAQ
What is QuickView?
What can my QuickView results tell me?
What are the sources for the General Info tab in QuickView?
More QuickView FAQs
Back to top
QuickView
Curated
Studies
Body
Atlas
Disease
Atlas
Pharmaco
Atlas
Knockdown
Atlas
Genetic
Markers
Pathway
Enrichment
Literature
Clinical
Trials
0
Meta-
Analysis
QuickView
Search sequence regions
(e.g.
Allergy to pollen
,
Endothelial cell
,
Laryngoscope
,
Lovastatin
,
rs4950928
,
PRKCA
)
Organisms
Chromosomes
Start
Stop
Homo Sapiens
Mus Musculus
Rattus Norvegicus
C. Elegans
D. Melanogaster
Saccharomyces Cerevisiae
QuickView
Go back to main search
Bookmark
Forward
QuickView
for
Siglec 15
Summary
General Info
Curated Studies
Most Correlated Studies
Differentiation of a circulating CCR9- pDC-like common dendritic cell precursor
Explore Curated Studies Results
Literature
Most Relevant Literature
Siglec15 is a prognostic indicator and a potential tumor-related macrophage regulator that is involv…
Structural insights into Siglec-15 reveal glycosylation dependency for its interaction with T cells …
Siglec-15 as multifunctional molecule involved in osteoclast differentiation, cancer immunity and mi…
Enhancing the Anti-tumor Potency of a Novel Siglec-15 Antibody by Engineering its Fc-mediated Effect…
Osteoclast-derived apoptotic bodies inhibit naive CD8+ T cell activation via Siglec15, promoting bre…
Explore Literature Results
Clinical Trials
Most Relevant Clinical Trials
Administration of Anti-siglec-6 CAR-T Cell Therapy in Relapsed and Refractory Acute Myeloid Leukemia…
"Don't Eat me" Signal in Hematological Malignancies: CD24 as New Target to Improve Anti-cancer Immun…
The Role of Emergency Neutrophils and Glycans in Postoperative and Septic Patients
Effect of Mepolizumab on Severe Eosinophilic Asthma
Cold Induced Changes in White Adipose
Explore Clinical Trials Results
search
→
result
search
→
result
See more about this page
See complete FAQ